pegaptanib (peg-apt-i-nib)

Name /bks_53161_deglins_md_disk/pegaptanib
02/17/2014 08:51AM
Plate # 0-Composite
pg 1 # 1
Interactions
Drug-Drug: None known.
1
pegaptanib (peg-apt-i-nib)
Macugen
Classification
Therapeutic: ocular agents
Pharmacologic: vascular endothelial growth-factor antagonists
Pregnancy Category B
PDF Page #1
Route/Dosage
Intravitreal (Adults): 0.3 mg every 6 wk.
NURSING IMPLICATIONS
Assessment
● Assess eye for signs of infection frequently during week following injection.
● Check perfusion of optic nerve head immediately after injection, use tonometry to
measure intraocular pressure within 30 min following the injection, and biomicroscopy between 2 and 7 days following injection. Increases in intraocular pressure have been seen within 30 min of injection.
Indications
Neovascular (wet) age-related macular degeneration.
Action
Acts as an antagonist of vascular endothelial growth factor (VEGF). VEGF may be responsible for the formation of incompetent, leaky blood vessels associated with macular degeneration. Therapeutic Effects: Decreased rate of loss of visual acuity.
Potential Nursing Diagnoses
Pharmacokinetics
Absorption: Slowly absorbed into systemic circulation after intravitreous adminis-
● Do not administer solutions that are discolored or contain particulate matter. At-
tration.
Distribution: Unknown.
Metabolism and Excretion: Metabolized by exo- and endonucleases.
Half-life: 10 days (plasma).
TIME/ACTION PROFILE
ROUTE
ONSET
PEAK
DURATION
Intravitreal
unknown
unknown
6 wk
Disturbed sensory perception (Indications)
Implementation
tach threaded plastic threader rod to the rubber stopper inside barrel of syringe.
Do not pull back on plunger.
● Adequate analgesia and a broad-spectrum antibiotic should be given prior to injection.
● Intravitreal: For ophthalmic intravitreal injection only.
Patient/Family Teaching
● Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive
to light, painful, or develops a change in vision.
Contraindications/Precautions
Contraindicated in: Ocular/periocular infections.
Use Cautiously in: OB: Use only if maternal benefit outweighs fetal risk; Lactation: Pedi: Safety not established.
Evaluation/Desired Outcomes
● Slowing of vision loss.
Why was this drug prescribed for your patient?
Adverse Reactions/Side Effects
EENT: cataract, blurred vision, conjunctival bleeding, irritation/pain,qintraocular
pressure, ocular inflammation, infection (rare), retinal detachment (rare), traumatic cataract formation (rare). Misc: Anaphylaxis, angioedema.
⫽ Canadian drug name.
⫽ Genetic Implication.
CAPITALS indicate life-threatening, underlines indicate most frequent.
Strikethrough ⫽ Discontinued.